Breaking News

Daily Archives: October 2, 2012

Lilly and Boehringer Ingelheim Present Health Outcomes Data for Investigational Novel Basal Insulin Analogue

BERLIN, Oct. 2, 2012 /PRNewswire — Eli Lilly and Company (NYSE: LLY) and Boehringer Ingelheim today announced patient-reported health outcomes data from a Phase II study of their investigational novel basal insulin analogue, LY2605541, in patients with type 2 diabetes. Study results showed that in addition to clinical results showing a statistically …

Read More »